Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,960.40
(
0.34%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.39
(
0.78%
)
Bitcoin
76,446.09
(
0.73%
)
News Focus
News Focus
Post# of 822147
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Chiugray

Send PM Follow Ignore
Followers 79
Posts 2280
Boards Moderated 0
Alias Born 01/31/2014

Chiugray

Re: Chiugray post# 536158

Sunday, 11/20/2022 6:47:37 PM

Sunday, November 20, 2022 6:47:37 PM

Post# of 822147
Adding onto my post about Murcidencel being ideal for oncologist considering Off-Label use and why insurance coverage will be welcomed because it saves money overall.

This from the JAMA Oncology Journal excerpt (page E7) on Murcidencel supports that.

The benign safety profile observed with DCVax-L can enable treatment of patients vulnerable to adverse events. Furthermore, it avoids the need (and cost) for other treatments to manage side effects.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News